Pharmacokinetics and Urinary Excretion Mechanism of Orteronel (TAK-700), A Novel 17,20-Lyase Inhibitor, in Animals

Abstract

Orteronel is newly identified as a selective 17,20-lyase inhibitor for an agent for castration resistant prostate cancer. The absorption and disposition of [¹⁴C]orteronel were investigated in rats and monkeys. Orteronel was extensively excreted into rat and monkey urine in an unchanged form after oral administration. The unbound based renal clearances in rats and monkeys were greater than the respective glomerular filtration rates (GFR), suggesting that urinary tubular secretion plays an important role in the renal excretion of orteronel. Therefore, the uptake of [¹⁴C]orteronel was investigated using rat kidney slices to estimate the contribution of carrier-mediated transport on the urinary tubular secretion. The uptake study using rat kidney slices suggested that the transport of orteronel from the blood circulation to the kidney was mediated by a digoxin sensitive transport system represented by Oatp4c1 and non-saturable components. Furthermore, the saturable component accounted for a limited fraction of the total renal uptake by rat kidney slices. These results suggested that non-saturable uptake mainly contributed to the renal excretion of orteronel in rats.

Key words

renal clearance - oatp4c1 - glomerular filtration rate

• References

• 1 Jemal A, Siegel R, Xu J et al. Cancer statistics, 2010. CA Cancer J Clin. 2010 60. 277-300
• 2 Kaku T, Hitaka T, Ojida A et al. Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. Bioorg Med Chem 2011; 19: 6383-6399
• 3 Petrylak DP, Gandhi JG, Clark WR et al. Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer. Invest New Drugs 2015;
• 4 Massard C, Fizazi K. Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res 2011; 17: 3876-3883
• 5 Hara T, Kouno J, Kaku T et al. Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats. J Steroid Biochem Mol Biol 2013; 134: 80-91
• 6 Yamaoka M, Hara T, Hitaka T et al. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. J Steroid Biochem Mol Biol 2012; 129: 115-128
• 7 FDA/CDER. Guidance for industry: drug interaction studies – study design, data analysis, implications for dosing, and labeling recommendations. 2012 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf
• 8 EMA. Guideline on the investigation of drug interactions. 2013 http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf
• 9 Suzuki K, Ozono S, Yamaguchi A et al. A phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 2015; 75: 373-380
• 10 Petrylak DP, Gandhi JG, Clark WR et al. Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer. Invest New Drugs 2015; 33: 397-408
• 11 Hasegawa M, Kusuhara H, Sugiyama D et al. Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions. J Pharmacol Exp Ther 2002; 300: 746-753
• 12 Yamaoka K, Tanigawara Y, Nakagawa T et al. A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn 1981; 4: 879-885
• 13 Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-1095
• 14 Urakami Y, Okuda M, Masuda S et al. Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther 1998; 287: 800-805
• 15 Sugiyama D, Kusuhara H, Shitara Y et al. Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier. J Pharmacol Exp Ther 2001; 298: 316-322
• 16 Nagata Y, Kusuhara H, Endou H et al. Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus. Mol Pharmacol 2002; 61: 982-988
• 17 Mikkaichi T, Suzuki T, Onogawa T et al. Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci USA 2004; 101: 3569-3574
• 18 Kuo KL, Zhu H, McNamara PJ et al. Localization and functional characterization of the rat Oatp4c1 transporter in an in vitro cell system and rat tissues. PLoS One 2012; 7: e39641